Spotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependence†

被引：0
作者：
Jennifer S. Orman
Gillian M. Keating
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
CNS Drugs | 2009年 / 23卷
关键词：
Clonidine; Naloxone; Buprenorphine; Withdrawal Syndrome; Opioid Antagonist;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Buprenorphine/naloxone (Suboxone®) comprises the partial μ-opioid receptor agonist buprenorphine in combination with the opioid antagonist naloxone in a 4: 1 ratio. When buprenorphine/naloxone is taken sublingually as prescribed, the naloxone exerts no clinically significant effect, leaving the opioid agonist effects of buprenorphine to predominate. However, when buprenorphine/naloxone is parenterally administered in patients physically dependent on full agonist opioids, the opioid antagonism of naloxone causes withdrawal effects, thus reducing the abuse potential of the drug combination.
引用
收藏
页码：899 / 902
页数：3
相关论文
共 57 条
  • [1] Orman JS(2009)Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence Drugs 69 577-607
  • [2] Keating GM(2006)Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences Toxicol Rev 25 79-85
  • [3] Mégarbane B(1978)Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction Arch Gen Psychiatry 35 501-16
  • [4] Hreiche R(1988)Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans J Pharmacol Exp Ther 247 47-53
  • [5] Pirnay S(1995)Effects of buprenorphine and methadone in methadone-maintained subjects Psychopharmacology (Berl) 119 268-76
  • [6] Jasinski DR(2004)Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S J Psychoactive Drugs 2 119-28
  • [7] Pevnick JS(1994)Clinical pharmacology of buprenorphine: ceiling effects at high doses Clin Pharmacol Ther 55 569-80
  • [8] Griffith JD(2006)Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials J Clin Pharmacol 46 179-92
  • [9] Bickel WK(1996)Buprenorphine’s physical dependence potential: antagonist-precipitated withdrawal in humans J Pharmacol Exp Ther 276 449-59
  • [10] Stitzer ML(1999)Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers Psychopharmacology (Berl) 141 37-46
123456